<SEC-DOCUMENT>0001193125-22-188799.txt : 20220707
<SEC-HEADER>0001193125-22-188799.hdr.sgml : 20220707
<ACCEPTANCE-DATETIME>20220706204753
ACCESSION NUMBER:		0001193125-22-188799
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220706
FILED AS OF DATE:		20220707
DATE AS OF CHANGE:		20220706

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		221070469

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d328207d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated July 6, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B><A HREF="d328207dex991.htm">IMMUTEP GRANTED JAPANESE PATENT FOR IMP761, A FIRST-IN-CLASS IMMUNOSUPPRESSIVE ANTIBODY TARGETING LAG-3</A></B></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: July 6, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d328207dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g328207pp.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP GRANTED JAPANESE PATENT FOR IMP761, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FIRST-IN-CLASS</FONT></FONT> IMMUNOSUPPRESSIVE ANTIBODY TARGETING <FONT
STYLE="white-space:nowrap">LAG-3</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; </B><B>6</B><B></B><B>&nbsp;July 2022 &#150;</B> <U>Immutep Limited</U> (ASX:
IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 7074341) entitled <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Anti-LAG-3</FONT></FONT> Antibodies&#148; by the Japanese Patent Office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This new
Japanese patent follows the grant of the equivalent European patent announced in October 2020. The claims of the patent are directed to Immutep&#146;s <FONT STYLE="white-space:nowrap">pre-clinical</FONT> product candidate IMP761, pharmaceutical
compositions comprising IMP761, and the use of the compositions in the treatment of <FONT STYLE="white-space:nowrap">T-cell</FONT> mediated inflammatory and autoimmune diseases. The expiry date of the patent is 1&nbsp;September 2036. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CEO, Marc Voigt stated</B>: &#147;We continue to take important steps to protect our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> candidate
IMP761, which is the first product candidate to act as a <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist, a novel mechanism of drug action that we believe can act directly to treat the root cause of autoimmune diseases. Of course, the <FONT
STYLE="white-space:nowrap">LAG-3</FONT> immune control mechanism has attracted a great deal of attention in recent months because of the approval by the FDA of the first <FONT STYLE="white-space:nowrap">LAG-3</FONT> related product in
immuno-oncology. With deep expertise in <FONT STYLE="white-space:nowrap">LAG-3</FONT> biology, four <FONT STYLE="white-space:nowrap">LAG-3</FONT> product candidates in development, and a comprehensive patent estate, Immutep is well placed to make
important contributions to this rapidly emerging field of immunotherapy - in both cancer and autoimmune diseases.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CSO and CMO,
Dr.</B><B></B><B>&nbsp;Frederic Triebel also stated</B>: &#147;We have been making good progress in advancing IMP761 towards clinical testing and, in recent months, have been working closely with Northway Biotech to develop a GMP compliant
manufacturing process using the cell line developed by Batavia BioSciences. It is also good to see continued progress in building our patent estate around this innovative <FONT STYLE="white-space:nowrap">LAG-3</FONT> candidate.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IMP761 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP761 is a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunosuppressive agonist antibody to <FONT STYLE="white-space:nowrap">LAG-3.</FONT> As a targeted immunosuppressive antibody, IMP761 has the potential to
address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells that accumulate at the disease site and which express <FONT STYLE="white-space:nowrap">LAG-3</FONT> as an &#147;exhaustion marker&#148; after being
repeatedly stimulated with dominant self-peptides. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In early 2019, Immutep reported encouraging <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
results from its studies with IMP761. The in vivo studies showed that IMP761 decreases inflammatory T cell infiltration induced by intra-dermal injection of an antigen. These findings were published in the <U>Journal of Immunology</U> in January
2020. Additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> research findings from a juvenile arthritis ex vivo model were published in <U>Pediatric Research</U> in May 2021. In these studies, IMP761 was shown to decrease effector T cell
cytokine secretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited,</B> Level 33, Australia Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 George Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g328207pp.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2021, Immutep announced that it had appointed Northway Biotech to develop a GMP compliant manufacturing process
and to manufacture IMP761 in large scale bioreactors, ahead of the commencement of clinical testing of the candidate in autoimmune diseases. The process will use a pharmaceutical-grade, stable CHO cell line developed by Batavia Biosciences that has
been shown to produce high product yields in a small-scale setup. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology company that is a leader in the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related
immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product
candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for
autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products, including antibodies for immune response modulation, are being developed by Immutep&#146;s large pharmaceutical partners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim McCarthy, LifeSci Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) 915.2564;&nbsp;<U>tim@lifesciadvisors.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the Board of Immutep Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited,</B> Level 33, Australia Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 George Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g328207pp.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g328207pp.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MCZ;CBMJ?PH[,/_#1LU9N% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 <]XG\*Q^)/LS&Z:WD@R 0NX$'&>/PH V-/LH]-TZWLHF9
MD@0("W4XH L$A>I ^M  "&&001[4 !8+U('UH 7Z4 % "%E7JP'U- "@@C(H
M 0LJG!(!^M "T % !0 4 <]XTU*[TKP\US92^5-YJKNP#P3SUH K> M0O-2T
M6>>]N'GD%P5#/V&U>* .JH * &B1"VT.I8=@: '4 '2@!H=6. P)]C0!4U73
M(=5L6MILC/*L.JGL:F45)6(J04XV9Q.HZ#JT<$%HM@DD<).)8>LF>Y%8.$MK
M'!.E424;;#M+\'WMS,K7J_9X!U&?G;V'I3C3;W"GAI-^]HCOXXTAB2.-0J(
MJ@=@*Z-CT4K:(=0,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M!RGB62\O?&5U8BZDVM.L2*SG:N0!T].: +]Q\.M8M(3-;7<,LBC.Q"R,?H:
M+O@KQ9=MJ"Z1J<K2!\K%))]Y6'\)]: /1: "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M1O\ KLG\Z (/AK_R+UQ_U\M_Z"M '8OD1MMZXXH \/T-=3DUI!I3;;_YMI)
M[<]>.F: .M-K\0R"#-Q_OQ?X4 .\'^%M9TCQ MU>6ZQP>6RDB13R<8X% &'J
MG_)2'_Z_8_YK0!Z_0!X[> )\1F\CJ-07&/7<,_KF@#V*@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M?MD;>8(F*XRO.<4 >K4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MX*+H.>/</M]G_P _</\ W\%%T'/'N'V^S_Y^X?\ OX*+H.>/</M]G_S]P_\
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D #/^%'*'LV']F3?],_S/^%'*'LV']F3?],_S/^%'*'LV?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
